GlassScriptPhysician profile
Paul Marcus Burgett
NPI 1962456327
$1,330.68
in general payments reported to CMS, 2019-2025
27 companies · $166 in 2025
The $166 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $79.11 · 2020: $27.07 · 2021: $159 · 2022: $238 · 2023: $196 · 2024: $466 · 2025: $166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $828.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $827.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $308.42 | 2024-2025 | Voquezna |
| Tela Bio, INC. | $84.94 | 2020-2024 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex), Ovitex 2s |
| Davol INC. | $84.87 | 2021-2024 | Arista Ah Flexitip |
| Boston Scientific Corporation | $81.69 | 2021-2024 | Spyglass Discover |
| Takeda Pharmaceuticals U.S.A., INC. | $78.27 | 2020-2024 | Gattex |
| Ethicon US, LLC | $72.72 | 2019-2024 | Stratafix |
| Lemaitre Vascular, INC. | $64.12 | 2023-2024 | Artegraft Vascular Graft, Anastoclip Gc 8cm (Medium) |
| Vertex Pharmaceuticals Incorporated | $58.90 | 2024-2025 | |
| Smith+Nephew, INC. | $54.18 | 2022-2025 | Stravix, Grafix Pl, Renasys Go V2 Home |
| Braintree Laboratories, INC. | $47.35 | 2022-2023 | Sutab, Suflave |
| Merck Sharp & Dohme LLC | $47.22 | 2019-2022 | |
| Csl Behring | $43.60 | 2022 | |
| Innovation Technologies INC | $38.52 | 2023 | Irrisept |
| Olympus America INC. | $35.41 | 2021 | |
| Stryker Corporation | $30.69 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Getinge USA Sales, LLC | $26.50 | 2021 | |
| Becton, Dickinson and Company | $26.02 | 2023 | Phasix Mesh |
| Coloplast Corp | $24.20 | 2024 | |
| Kerecis Limited | $19.53 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Kls-Martin L.P. | $17.71 | 2024 | |
| Heron Therapeutics, INC. | $16.65 | 2023 | Zynrelef |
| Acera Surgical, INC. | $16.19 | 2022 | |
| Bard Peripheral Vascular, INC. | $14.88 | 2024 | Glidepath |
| Solventum Corporation | $13.12 | 2024 | Prevena |
| Tei Biosciences INC | $11.76 | 2019 | |
| Zimmer Biomet Holdings, INC. | $11.44 | 2019 | |
| Organogenesis INC. | $1.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Burgett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.